Respiratory Syncytial Virus Vaccine Approaches: a Current Overview.

Abstract

PURPOSE OF REVIEW:

Respiratory syncytial virus (RSV) is a global human pathogen responsible for lower respiratory tract infections (LRTI). While RSV infection is innocuous in healthy adults, it is the leading cause of infant hospitalization for respiratory tract infection. Nearly everyone shows evidence of an RSV infection by the age of 3. However, there is still not a vaccine commercially available. This review will provide an update on the clinical and preclinical vaccine studies and different approaches to prevent RSV infection.

RECENT FINDINGS:

Novel vaccine approaches that induce protection against RSV without enhancement of respiratory tract disease.

SUMMARY:

Recent technological approaches have led to generation of different strategies to prevent RSV infection, including live attenuated, chimeric, and subunit vaccines, virus-like particles, and nanoparticles. These vaccine approaches represent promising candidates towards an efficient RSV vaccine that effectively protects infants, children, and adults.

• Authors: Carolyn M Clark, Antonieta Guerrero-Plata
• Journal: Current clinical microbiology reports (Curr Clin Microbiol Rep) Vol. 4 Pg. 202-207 (Dec 2017) ISSN: 2196-5471 [Print] Switzerland
• PMID: 30009126 (Publication Type: Journal Article)